Drug Search Results
More Filters [+]


Alternative Names: jw-200, jw200, jw 200
Latest Update: 2023-06-28
Latest Update Note: Clinical Trial Update

Product Description

JW-200 was developed by Jupiter Wellness in order to treat patients with actinic keratosis. (Sourcd from: https://www.sec.gov/Archives/edgar/data/1760903/000149315221024981/ex99-1.htm)

Mechanisms of Action: COX2 Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jupiter Wellness
Company Location: JUPITER FL 33458
Company CEO: Brian S. John
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JW-200

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Keratosis, Actinic



Trial Status


Primary Completion Date

Probability of Success

Recent News Events